CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
BI 1015550 +1 moredrug
Likely dose
BI 1015550 6 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03403439
NCT03403439Phase 1Completed

Relative Bioavailability of a Single Oral Dose of BI 1015550 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Boehringer Ingelheim·interventional·Posted Jan 18, 2018·Updated Nov 28, 2025

In Brief

A Phase 1 clinical trial evaluating BI 1015550 and itraconazole for Healthy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The primary objective of this trial is to investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI1015550, i.e. to compare the relative bioavailability of 6 mg BI 1015550 when given alone (reference, treatment R) to the relative bioavailability of 6 mg of BI 1015550 given on the 4th day of a 12-day-treatment with itraconazole (test, treatment T) following oral administration in healthy male subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJan 18, 2018
Enrollment StartMay 3, 2018
Primary CompletionJul 20, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.5 years ago

Interventions

BI 1015550drug

single dose of BI 1015550 6 milligram (mg) tablet orally with 240 milliLitre (mL) of water after an overnight fast of at least 10 hours

itraconazoledrug

200 mg itraconazole solution given orally once daily with 240 mL of water after an overnight fast of at least 9 h